3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
127
Neoplasm Metastasis
14
Neoplasms
9
Advanced Breast Cancer
6
Endometrial Neoplasms
5
Recurrence
4
Hereditary Sensory and Autonomic Neuropathies
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms, Hormone-Dependent
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Lobular
3
Carcinoma, Ductal, Breast
3
Squamous Cell Carcinoma of Head and Neck
2
Polycystic Ovary Syndrome
2
Osteoporosis
2
Neoplasms by Site
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Breast Neoplasms, Male
2
Breast Diseases
2
Bone Diseases, Metabolic
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Osteitis Deformans
1
Multiple Endocrine Neoplasia Type 1
1
Mesothelioma, Malignant
1
Interventions
Letrozole
2
ribociclib
1
palbociclib
1
abemaciclib
1
Fulvestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
HR+/HER2- Breast Cancer
×
Letrozole
×
Clear all
NCT07492641
2026-06-03
KANDELA-302
BeOne Medicines
Phase 3
Recruiting
1,056 enrolled
NCT06998407
2026-05-04
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2
Recruiting
380 enrolled